Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7795305 CDDO-compounds and combination therapies thereof

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Marina Konopleva0

Michael Andreeff0

Michael B. Sporn0

Date of Patent

September 14, 2010

0

Patent Application Number

122495880

Date Filed

October 10, 2008

0

Patent Citations Received

US Patent 12065464 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

0

US Patent 11873320 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

0

US Patent 11911395 Methods of treating obesity using antioxidant inflammation modulators

0

US Patent 11919838 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17

0

US Patent 11993574 Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma

0

US Patent 12060340 Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith

0

Patent Primary Examiner

James D. Anderson

0

Patent abstract

CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7795305 CDDO-compounds and combination therapies thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.